Skip to main content

Clinical Trials Using Cyclophosphamide

Review the clinical trials studying cyclophosphamide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 401-417 of 417

Autologous Anti-NY-ESO-1 TCR-Engineered T Cells for the Treatment of Patients with Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
Status: Temporarily Closed to Accrual
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults with Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial
Status: Temporarily Closed to Accrual
Location: 6 locations
Venetoclax, Busulfan, Fludarabine, Azacitidine, Decitabine, and Cedazuridine in Treating Patients with High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndromes Undergoing Donor Stem Cell Transplantation
Status: Temporarily Closed to Accrual
Location: 2 locations
Standard versus Low Dose Cyclophosphamide for Prevention of GVHD and Improvement in Quality of Life after Donor Stem Cell Transplant among Older Adults with Hematological Cancers
Status: Active
Location: University of Nebraska Medical Center, Omaha, Nebraska
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients with Blood Cancer Undergoing a Donor Stem Cell Transplant
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Real-Time Circulating Tumor Deoxyribonucleic Acid Sequencing to Guide Therapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma, SHORTEN-ctDNA Trial
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Itacitinib for the Prevention of Graft Versus Host Disease
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
A Study of Ruxolitinib for Preventing Graft-versus-Host Disease in People with a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Status: Active
Location: 7 locations
Belumosudil for the Prevention of Graft-versus-Host Disease after Donor Hematopoietic Cell Transplant
Status: Active
Location: 7 locations
Immune Suppression Treatment for People With Sickle Cell Disease or Beta-Thalassemia Who are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Active
Location: 7 locations
Cyclophosphamide, Tacrolimus, and Ruxolitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Myeloablative Allogeneic Stem Cell Transplant
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Post-Transplant Cyclophosphamide for the Prevention of Graft Versus Host Disease in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning for Hematological Diseases
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Abatacept for the Prevention of Graft Versus Host Disease after Cord Blood Transplant in Patients with Hematologic Blood Cancers, ABBA CORD Trial
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Abatacept in Combination with Mycophenolate Mofetil and Tacrolimus for the Prevention of Graft-versus-Host Disease after Omidubicel Hematopoietic Cell Transplant
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Selection of CD34 Positive Stem Cells using CliniMACS Prodigy Device for the Prevention of Graft-versus-Host Disease
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Rapid Infusion of Dinutuximab with Chemotherapy for the Treatment of Relapsed, Refractory or Persistent High Risk Neuroblastoma or Ganglioneuroblastoma
Status: Active
Location: Children's Hospital Los Angeles, Los Angeles, California
Implantable Microdevice for the Delivery of Drugs and their Effect on Tumors in Patients with Sarcoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas